Experimental cancer combo trial halted early

NCT ID NCT05147350

Terminated Disease control Sponsor: Debiopharm International SA Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new drug called RP-6306 combined with standard chemotherapy (FOLFIRI) in 38 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumors. However, the study was terminated early, so no final results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RP-6306 (a PKMYT1 inhibitor) combined with FOLFIRI chemotherapy
What this could lead to: If successful, this could point toward a new combination treatment for advanced solid tumors that have stopped responding to standard therapy.
What could go wrong: This was a very early (Phase 1) trial that was terminated, so no conclusions can be drawn. The combination may cause significant side effects, and it is unclear if it will work in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

# 2001, Princess Margaret Cancer Centre

Toronto, Ontario, ON M5G 2M9, Canada
# 3003, Sarah Cannon Research Institute

London, W1G 6AD, United Kingdom
# 5002, South Texas Accelerated Research Therapeutics

Madrid, Spain
# 5003, Hospital Universitario HM Sanchinarro

Madrid, Spain
#1001, The University of Texas M.D. Anderson Cancer Center

Houston, Texas, 77030, United States
#1008, Columbia University

New York, New York, 10032, United States
#1013, The University of Utah, Huntsman Cancer Center

Salt Lake City, Utah, 84112, United States
#1019, UCLA, Westwood Cancer Center

Los Angeles, California, 90095, United States
#1022, Moffitt Cancer Center

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.